Tabula Rasa HealthCare (TRHC) Tops Q4 EPS by 9c, Revenues Beat; Offers Q1 & FY20 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Tabula Rasa HealthCare Announces Fourth Quarter and Full Year 2019 Results
February 27, 2020 4:06 PM ESTMOORESTOWN, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today announced its financial results for the fourth quarter and full year ended December 31, 2019.
Full Year 2019 Highlights
Total revenue increased 39% to $284.7 million;Non-GAAP Adjusted EBITDA increased 29% to $37.9 million;Non-GAAP Adjusted diluted EPS increased to $0.79 from $0.77;Product revenue increased 22% to $137.1 million, driven by growth in the number of participants enrolled in PACE organizations of 14% and an incremental $9.8 million of cross-sell revenue recognized during 2019;... More


